OC-0062: Phase II trial of SBRT and hormone therapy for oligometastases in prostate cancer (SBRT-SG 05)

Moreno, A.; Campos, F. López; Morón, A. Hervás; Ocaña, C. Vallejo; Albarran, J. Valero; Villamón, A. Méndez; Valiño, M.M. Puertas; Gómez-Iturriaga, A.; Ots, P. Samper; Galarza, A. Sola; Osés, Maddi; Villaoslada, C. Ibañez; Pérez-Romasanta, Luis A.; Peidro, J. Pastor; López-Torrecilla, J.; Gonzalez, F. Ferrer; Rodil, N. Ortiz; Piñon, F. García; Pérez, E Rodríguez; Albiach, C. Ferrer

doi:10.1016/s0167-8140(18)30372-4

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oligoprogressive patients: Special mention must be made of the assessment of SBRT in oligoprogressive patients. Five series[30,47,49,50] include oligorecurrent and oligoprogressive, castration-resistant patients. Stereotactic body radiation therapy appears to be useful also in this group of patients with a poorer prognosis.…”

Section: Sbrt Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Oligometastases in prostate cancer: Ablative treatment

Palacios-Eito

Béjar-Luque

Rodríguez-Liñán

et al. 2019

WJCO

View full text Add to dashboard Cite

Technological advances in radiotherapy have led to the introduction of techniques such as stereotactic body radiation therapy (SBRT), allowing the administration of ablative doses. The hypothesis that oligometastatic disease may be cured through local eradication therapies has led to the increasing use of SBRT in patients with this type of disease. At the same time, scientific advances are being made to allow the confirmation of clinically suspected oligometastatic status at molecular level. There is growing interest in identifying patients with oligometastatic prostate cancer (PCa) who may benefit from curative intent metastasis-directed therapy, including SBRT. The aim is to complement, replace or delay the introduction of hormone therapy or other systemic therapies. The present review aims to compile the evidence from the main ongoing studies and results on SBRT in relation to oligometastatic PCa; examine aspects where gaps in knowledge or a lack of consensus persist ( e.g ., optimum schemes, response assessment, identification and diagnosis of oligometastatic patients); and document the lack of first-level evidence supporting the use of such techniques.

show abstract

Section: Sbrt Resultsmentioning

confidence: 99%

“…In the Spanish phase II of the GICOR group[50], all patients had at least two years of ADT prior to SBRT, and 12 cases of oligoprogression were included, of which 66% with a median follow-up of 9.8 mo remained progression-free without the need for a new line of systemic treatment (hormonal or chemotherapy).…”

Section: Sbrt Resultsmentioning

confidence: 99%

Oligometastases in prostate cancer: Ablative treatment

Palacios-Eito

Béjar-Luque

Rodríguez-Liñán

et al. 2019

WJCO

View full text Add to dashboard Cite

show abstract

Oligometastatic prostate cancer: The game is afoot

Lancia

Zilli

Achard

et al. 2019

Cancer Treatment Reviews

View full text Add to dashboard Cite

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence

Viani

Arruda

Hamamura

et al. 2019

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Purpose: The purpose of this study was to evaluate the treatment efficacy of stereotactic body radiotherapy (SBRT) in oligometastatic prostate cancer recurrence and to assess whether there is any relationship between biologically effective dose (BED) and local control (LC). Materials and Methods: Eligible studies were identified on Medline, Embase, and the Cochrane Library, and the proceedings of annual meetings through May 2019 were also identified. A meta-regression analysis was performed to assess whether there is a relationship between BED and LC. In the univariate analysis, studies were separated by the study design, the number of metastatic sites, the site of metastases, radiotherapy machine, and prostate-specific antigen level at the time of SBRT. A P-value <0.05 was considered significant. Results: Twenty-three observational studies with a total of 1441 lesions treated were included in the meta-analysis. The proportional rate of LC, progression-free survival, and androgen deprivation–free survival was 0.976 (95% confidence interval [CI]: 0.96-0.98), 0.413 (95% CI: 0.378-0.477), and 20.1 months (95% CI: 14.5-25.6), respectively. In the meta-regression, a linear relationship between BED and LC was detected (P=0.017). Stratifying the BED into 3 levels (BED<100 Gy3, BED 100 to 130 Gy3, and BED>130 Gy3), a significant difference was observed between BED<100 Gy3 (LC=88%) versus BED>100 Gy3 (LC=96%). The rate of any acute and late grade ≥2 toxicity was 1.3% and 1.2%, respectively. Conclusions: The LC rate with SBRT was excellent with minimal severe acute/late toxicity. Our data suggest a dose relationship between BED and LC, with BED >100 Gy3 resulting in better rates of LC.

show abstract

OC-0062: Phase II trial of SBRT and hormone therapy for oligometastases in prostate cancer (SBRT-SG 05)

Cited by 3 publications

References 0 publications

Oligometastases in prostate cancer: Ablative treatment

Oligometastases in prostate cancer: Ablative treatment

Oligometastatic prostate cancer: The game is afoot

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence

Contact Info

Product

Resources

About